Phase 3 trial finds retatrutide reduces weight, osteoarthritis pain, apnea events

This phase 3 randomized, double-blind trial (TRIUMPH-1) tested once-weekly subcutaneous retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, at 4, 9, or 12 mg versus placebo in 2339 adults with obesity without diabetes over 80 weeks. The trial reported mean weight loss of 17.6%, 23.7%, and 25.0% across doses versus 3.9% with placebo, along with greater reductions in WOMAC knee pain scores among participants with knee osteoarthritis and greater reductions in apnea-hypopnea index among participants with obstructive sleep apnea, with gastrointestinal events being the most common adverse events.

Most relevant for: Adults with obesity, including those with comorbid knee osteoarthritis or obstructive sleep apnea, who do not have diabetes.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.